Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial.
Explore this paper's citation graph
Summary
Allopurinol does not appear to reduce the overall risk of PEP; however, its potential benefit in the high-risk group (but potential harm for non-high-risk patients) means further study is required.
- Type
- article
- Published
- 2008-04-01
- Cited by
- 31
- References
- 54
- OpenAlex
- https://openalex.org/W2034153914
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:22384324
Keywords
Medicine, Allopurinol, Endoscopic retrograde cholangiopancreatography, Pancreatitis, Internal medicine
References
- Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials.
- "Compendium of pharmaceuticals and specialties".
- N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis.
- Clinical Trials : A Methodologic Perspective
- Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials
- Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
- Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study.
- Complications of Endoscopic Biliary Sphincterotomy: A Review
- Risk Factors for Post-ERCP Pancreatitis: A Prospective Multicenter Study
- Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis.
- Effect of Octreotide Administration in the Prophylaxis of Post-ERCP Pancreatitis and Hyperamylasemia: A Multicenter, Placebo-Controlled, Randomized Clinical Trial
- A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
- Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
- Stent-induced pancreatic ductal and parenchymal changes: correlation of endoscopic ultrasound with ERCP.
- Indomethacin May Reduce the Incidence and Severity of Acute Pancreatitis After ERCP
- Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification.
- Allopurinol protects enterocytes from hypoxia-induced apoptosis in vivo.
- Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial.
- Severe and fatal complications after diagnostic and therapeutic ERCP: a prospective series of claims to insurance covering public hospitals.
- The Role of Oxygen‐derived Free Radicals in the Pathogenesis of Acute Pancreatitis
Cited by
- Endoscopic retrograde cholangiopancreatography associated pancreatitis: A 15-year review.
- Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: What does evidence suggest?
- PHARMACOLOGIC PROPHYLAXIS OF POST-ERCP PANCREATITIS: IS ALLOPURINOL THE ANSWER?
- Advances in pancreatobiliary endoscopy
- Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials.
- Meta‐analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis
- Prevention Effect of Allopurinol on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Meta-Analysis of Prospective Randomized Controlled Trials
- Identifying and reporting risk factors for adverse events in endoscopy. Part I: cardiopulmonary events.
- Risk of post-endoscopic retrograde cholangiopancreatography pancreatitis and ways to prevent it: old myths, a current need? The case of allopurinol.
- Prevention of Post-ERCP Pancreatitis
- Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
- Is High-Dose Nafamostat Mesilate Effective for the Prevention of Post-ERCP Pancreatitis, Especially in High-Risk Patients?
- Advances in managing acute pancreatitis
- Role of Oxidative Stress in Pancreatic Inflammation
- Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography.
- Quality measurement and improvement in advanced procedures
- Antioxidant therapy effectiveness: an up to date.
- Antioxidant therapy in the management of acute, chronic and post-ERCP pancreatitis: a systematic review.
- Antioxidant supplementation for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials
- Antioxidant therapy in acute, chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis: An updated systematic review and meta-analysis.
Related papers
- Allopurinol: xanthine oxidase inhibitor.
- THE EFFECTIVENESS OF THE XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN THE TREATMENT OF GOUT.
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
- Agranulocytosis: an adverse effect of allopurinol treatment
- Contraindications of Concomitant Use of Azathioprine and Allopurinol on Drug Package Inserts: Case Study and Comparison of New and Existing Issues of Novel Xanthine Oxidase Inhibitor
- Agranulocytosis: an adverse effect of allopurinol treatment
- Stereochemistry of nucleic acids and their constituents. XXIX. Crystal and molecular structure of allopurinol, a potent inhibitor of xanthine oxidase
- Allopurinol (xanthine oxidase inhibitor) in the treatment of resistant gout
- Allopurinol (xanthine oxidase inhibitor) in the treatment of resistant gout.